| Patent application number | Description | Published |
|---|
| 20080267943 | Innate Immune Receptor Directed Biocides - The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing). The present invention also relates to methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in various diagnostic applications in number of diverse fields such as agriculture, medicine, and national defense. | 10-30-2008 |
| 20080269122 | Antimicrobial Peptide Biocides - The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing). The present invention also relates to methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in various diagnostic applications in number of diverse fields such as agriculture, medicine, and national defense. | 10-30-2008 |
| 20080274095 | Biocides - The present invention relates to the use of biocide (e.g., bactericidal enzyme) to target pathogens. In particular, the present invention provides biocides for use in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., water purification). | 11-06-2008 |
| 20090098121 | Immunoglobulin Directed Biocides - The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing). The present invention also relates to methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in various diagnostic applications in number of diverse fields such as agriculture, medicine, and national defense. | 04-16-2009 |
| 20100111976 | TARGETED BIOCIDES - The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing). The present invention also relates to methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in various diagnostic applications in number of diverse fields such as agriculture, medicine, and national defense. | 05-06-2010 |
| 20100183611 | TARGETED CRYPTOSPORIDIUM BIOCIDES - The present invention relates to fusion proteins comprising a microorganism targeting molecule (e.g., immunoglobulin) and a biocide. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in diverse fields. | 07-22-2010 |
| Patent application number | Description | Published |
|---|
| 20100179492 | METHODS FOR INCREASING TRICHOGENICITY OF DERMAL CELLS - Methods for increasing trichogenic activity of populations of dermal cells by inducing local trauma to skin tissue that serves as a source of the dermal cells are provided. Methods for obtaining dermal cells with increased trichogenic activity and for using the disclosed dermal cells to implant into a mammalian host at a site of desired follicle generation are also provided. | 07-15-2010 |
| 20100291580 | BIOMARKERS FOR TRICHOGENICITY - Biomarkers for identifying trichogenic cells have been identified. The biomarkers include microRNA as wells as mRNA and proteins. Certain biomarkers are upregulated in trichogenic cells compared to non-trichogenic cells; whereas, other biomarkers are down-regulated in trichogenic cells compared to non-trichogenic cells. The cells can be dermal cells, epidermal cells, or a combination thereof. Preferably the cells are mammalian, more preferably the cells are human. One embodiment provides a method for selecting trichogenic cells by assaying the cells for expression of one or more biomarkers for trichogenicity, and selecting the cells having increased expression of the one or more biomarkers relative to a control, wherein increased expression of the a biomarker in the cells is indicative of trichogenicity. Preferably, the one or more biomarkers are selected from the group consisting of hsa-miR-200c, hsa-miR-205, hsa-miR-200a*, hsa-miR-200a, hsa-miR-141, hsa-miR-182, DEPDC1, hFLEG1, ESM1, TOME-1, THBD and combinations thereof. | 11-18-2010 |
| 20120022433 | METHODS FOR INCREASING TRICHOGENICITY OF DERMAL CELLS - Methods for increasing trichogenic activity of populations of dermal cells by inducing local trauma to skin tissue that serves as a source of the dermal cells are provided. Methods for obtaining dermal cells with increased trichogenic activity and for using the disclosed dermal cells to implant into a mammalian host at a site of desired follicle generation are also provided. | 01-26-2012 |
| 20120095445 | METHODS AND COMPOSITIONS FOR INCREASING TRICHOGENIC POTENCY OF DERMAL CELLS - Methods and compositions for increasing trichogenicity of cells in culture are provided. One embodiment provides culturing dissociated mammalian dermal cells in vitro in the presence of an effective amount of one or more sonic hedgehog (Shh) pathway agonists to increase the trichogenicity of the dissociated mammalian dermal cells compared to untreated dissociated mammalian dermal cells. The cell culture optionally includes epidermal cells. Preferred Shh agonists include, but are not limited to CUR-0236715 and CUR-0201365 available from Curis, Inc. Trichogenicity is measured using the Aderans Hair Patch Assay™. The cultured dermal cells can be maintained in culture in the presence of the one or more Shh agonists for at least 1 to 7 or more days prior to harvest. The treated, cultured dermal cells can be used to treat hair loss in a mammalian subject, preferably a human, by implanting them in an effective amount to induce hair follicle formation. | 04-19-2012 |
